Recently Viewed
Clear All$3.54
$-0.36
(-9.23%)
As on 02-Apr-2026 16:16EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$527 Mln
Revenue (TTM)
$296 Mln
Net Profit (TTM)
$0 Mln
ROE
-5.7 %
ROCE
-- %
P/E Ratio
21.5
P/B Ratio
2.6
Industry P/E
--
EV/EBITDA
8.4
Div. Yield
0 %
Debt to Equity
-2.3
Book Value
$--
EPS
$0.1
Face value
--
Shares outstanding
163,058,316
CFO
$440.27 Mln
EBITDA
$505.10 Mln
Net Profit
$-1,021.16 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
| 5.0 | 3.5 | 5.0 | 151.1 | -30.4 | -20.1 | -9.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
| -23.9 | -61.0 | -7.7 | 6.3 | 2.4 | -14.4 | 53.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
|
3.5 | 526.7 | 296.2 | 24.0 | 40.7 | -8.5 | 21.5 | 2.6 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase... type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Address: 100 Summer Street, Boston, MA, United States, 02110 Read more
Executive Chairman of the Board
Ms. Julie H. McHugh
Executive Chairman of the Board
Ms. Julie H. McHugh
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ironwood Pharmaceuticals Inc Class A (IRWD) is $3.54 (NASDAQ) as of 02-Apr-2026 16:16 EDT. Ironwood Pharmaceuticals Inc Class A (IRWD) has given a return of -30.44% in the last 3 years.
The P/E ratio of Ironwood Pharmaceuticals Inc Class A (IRWD) is 21.53 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
24.94
|
-2.29
|
|
2024
|
807.56
|
-2.36
|
|
2023
|
-1.78
|
-5.15
|
|
2022
|
13.11
|
3.52
|
|
2021
|
3.65
|
3.19
|
The 52-week high and low of Ironwood Pharmaceuticals Inc Class A (IRWD) are Rs 5.78 and Rs 0.53 as of 03-Apr-2026.
Ironwood Pharmaceuticals Inc Class A (IRWD) has a market capitalisation of $ 527 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ironwood Pharmaceuticals Inc Class A (IRWD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.